SPPI Spectrum Pharmaceuticals Inc

• Poziotinib:
  • Objective Response Rate of 73% was observed in preliminary analysis from an ongoing Phase 2 study conducted by MD Anderson Cancer Center in Non-Small-Cell Lung Cancer (NSCLC) patients with EGFR exon 20 insertion mutations.
  • The Company has initiated a multicenter clinical trial to expedite the development of poziotinib in lung cancer patients with exon 20 insertion mutations.
• ROLONTISTM (eflapegrastim):
  • Topline results expected in Q1 2018 from the fully enrolled ADVANCE Study under a Special Protocol Assessment (SPA) from the FDA.
  • RECOVER, a second smaller Phase 3 study, is enrolling patients internationally.
  • BLA filing expected in Q4 2018.
• QAPZOLA®:
  • Phase 3 study under an SPA is currently enrolling patients.
• Financials:
  • Q3 revenues were $36.4 million, including $31.2 million in product sales.

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced today financial results for the three-month period ended September 30, 2017.

"We have been focused on developing our late-stage pipeline and I am proud of our progress,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals. “Encouraging data from the Phase 2 lung cancer study from poziotinib was presented at the World Conference on Lung Cancer in Japan two weeks ago. We remain very excited about poziotinib’s prospects in lung cancer as well as other solid tumors. We also look forward to receiving top-line results from ROLONTIS’s ADVANCE registrational Phase 3 study in the first quarter of 2018. We are enthusiastic about developing our pipeline strategically and expeditiously.”

Pipeline Update:

• Poziotinib, an irreversible tyrosine kinase inhibitor: Three Phase 2 studies evaluating poziotinib in lung cancer and breast cancer are currently enrolling patients in the U.S.
  • An investigator sponsored trial is currently enrolling at the University of Texas MD Anderson Cancer Center in non-small cell lung cancer patients with exon 20 insertion mutations in EGFR or HER2. The study yielded preliminary results demonstrating evidence of significant antitumor activity in NSCLC patients with EGFR exon 20 insertion mutations, with preliminary data showing an Objective Response Rate of 73%. Toxicities have included rash, diarrhea, paronychia, and mucositis consistent with those previously described for poziotinib and other TKIs, which led to dose reduction in 55% of the patients.
  • In consultation with the FDA, the Company has initiated a multicenter study. This trial will enroll up to 87 patients with EGFR exon 20 insertion mutations and up to 87 patients with HER2 exon 20 insertion mutations at several leading cancer institutions. The study will evaluate objective response rate (ORR) as the primary endpoint, and disease control rate (DCR), duration of response (DOR), and safety as secondary endpoints.
  • Spectrum is also conducting a Phase 2 breast cancer study in the third-line setting in the U.S.
• ROLONTIS (eflapegrastim), a novel long-acting GCSF: A registrational Phase 3 study ADVANCE was initiated under an SPA with the FDA last year to evaluate ROLONTIS in the management of chemotherapy-induced neutropenia. The Company has completed enrollment in the ADVANCE study with 406 patients randomized and expects to report topline data in Q1 2018. To strengthen the regulatory package in Europe and the U.S., the Company is currently enrolling the 218-patient international RECOVER study, which has a similar design. The Company expects to file the BLA in Q4 2018.
• QAPZOLA, a potent tumor-activated drug for bladder cancer is being investigated for low and intermediate risk non-muscle invasive bladder cancer: The Company has an SPA from the FDA and is currently enrolling patients in a Phase 3 study. The Phase 3 study has incorporated learnings from the previous studies, as well as recommendations from the FDA. The Phase 3 study will enroll approximately 425 evaluable patients, using a single dose of 8 mg, and will evaluate time-to-recurrence as the primary endpoint.

Three-Month Period Ended September 30, 2017 (All numbers are approximate)

GAAP Results

Total product sales were $31.2 million in the third quarter of 2017. Product sales in the third quarter included: FUSILEV® (levoleucovorin) net sales of $1.8 million, FOLOTYN® (pralatrexate injection) net sales of $11.6 million, ZEVALIN® (ibritumomab tiuxetan) net sales of $2.7 million, MARQIBO® (vinCRIStine sulfate LIPOSOME injection) net sales of $1.2 million, BELEODAQ® (belinostat) for injection net sales of $3.4 million, and EVOMELA® (melphalan) for injection net sales of $10.5 million.

Spectrum recorded a net loss of $18.7 million, or $0.22 per basic and diluted share in the three-month period ended September 30, 2017, compared to a net loss of $17.5 million, or $0.22 per basic and diluted share in the comparable period in 2016. Total research and development expenses were $13.9 million in the quarter, as compared to $13.3 million in the same period in 2016. Selling, general and administrative expenses were $18.9 million in the quarter, compared to $19.5 million in the same period in 2016.

Our September 30, 2017 cash and equivalents balance is $248 million.

Non-GAAP Results

Spectrum recorded non-GAAP net loss of $9.2 million, or $0.11 per basic and diluted share in the three-month period ended September 30, 2017, compared to non-GAAP net loss of $5.3 million, or $0.07 per basic share and diluted share in the comparable period in 2016. Non-GAAP research and development expenses were $13.2 million, as compared to $12.8 million in the same period of 2016. Non-GAAP selling, general and administrative expenses were $16.1 million, as compared to $15.6 million in the same period in 2016.

Conference Call

Thursday, November 2, 2017 @ 4:30 p.m. Eastern/1:30 p.m. Pacific

    Domestic:   (877) 837-3910, Conference ID# 7488227 International: (973) 796-5077, Conference ID# 7488227

This conference call will also be webcast. Listeners may access the webcast, which will be available on the investor relations page of Spectrum Pharmaceuticals' website: www.sppirx.com on November 2, 2017 at 4:30 p.m. Eastern/1:30 p.m. Pacific.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the Company. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.

Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC. ®, FUSILEV®, FOLOTYN®, ZEVALIN®, MARQIBO®, BELEODAQ®, EVOMELA®and QAPZOLA® are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING CANCER CARE™, ROLONTIS™, and the Spectrum Pharmaceuticals' logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 2017 Spectrum Pharmaceuticals, Inc. All Rights Reserved

  SPECTRUM PHARMACEUTICALS, INC. Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

    Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2017   2016 2017   2016 Revenues: Product sales, net $ 31,234 $ 30,272 $ 88,235 $ 96,401 License fees and service revenue 5,161   3,121   11,562   14,807   Total revenues 36,395   33,393   99,797   111,208   Operating costs and expenses: Cost of sales (excludes amortization and impairment charges of intangible assets) 12,179 7,503 31,618 18,715 Cost of service revenue — 2,221 4,221 5,716 Selling, general and administrative 18,880 19,465 54,595 69,047 Research and development 13,878 13,293 43,670 43,037 Amortization and impairment charges of intangible assets 6,928   6,907   20,718   19,052   Total operating costs and expenses 51,865   49,389   154,822   155,567   Loss from operations (15,470 ) (15,996 ) (55,025 ) (44,359 ) Other (expense) income: Interest expense, net (2,014 ) (2,373 ) (6,196 ) (7,087 ) Change in fair value of contingent consideration related to acquisitions (2,942 ) 78 (3,236 ) (1,249 ) Other income, net 251   372   901   990   Total other expenses (4,705 ) (1,923 ) (8,531 ) (7,346 ) Loss before income taxes (20,175 ) (17,919 ) (63,556 ) (51,705 ) Benefit for income taxes 1,466   464   1,412   635   Net loss $ (18,709 ) $ (17,455 ) $ (62,144 ) $ (51,070 ) Net loss per share: Basic and diluted $ (0.22 ) $ (0.22 ) $ (0.78 ) $ (0.73 ) Weighted average shares outstanding: Basic and diluted 83,463,153   79,303,380   80,177,370   70,437,885       SPECTRUM PHARMACEUTICALS, INC. Condensed Consolidated Balance Sheets

(In thousands, expect per share and par value amounts)

(Unaudited)

    September 30, 2017 December 31, 2016 ASSETS Current assets: Cash and cash equivalents $ 247,468 $ 158,222 Marketable securities 248 247 Accounts receivable, net of allowance for doubtful accounts of $88 and $88, respectively 37,767 39,782 Other receivables 5,876 5,754 Inventories 8,983 8,715 Prepaid expenses and other assets 2,957   3,930   Total current assets 303,299 216,650 Property and equipment, net of accumulated depreciation 615 449 Intangible assets, net of accumulated amortization and impairment charges 144,036 164,234 Goodwill 18,131 17,886 Other assets 35,736   29,549   Total assets $ 501,817   $ 428,768   LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable and other accrued liabilities $ 49,635 $ 52,483 Accrued payroll and benefits 7,636 8,981 Deferred revenue 2,783 3,188 FOLOTYN development liability 153   861   Total current liabilities 60,207   65,513   FOLOTYN development liability, less current portion 12,273 12,269 Deferred revenue, less current portion 324 323 Acquisition-related contingent obligations 4,551 1,315 Deferred tax liabilities 6,829 6,675 Other long-term liabilities 11,127 9,604 Convertible senior notes 101,770   97,043   Total liabilities 197,081 192,742 Commitments and contingencies Stockholders’ equity: Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding — — Series B junior participating preferred stock, $0.001 par value; 1,500,000 shares authorized; no shares issued and outstanding — — Series E convertible voting preferred stock, $0.001 par value and $10,000 stated value; 2,000 shares authorized; no shares issued and outstanding. — — Common stock, $0.001 par value; 175,000,000 shares authorized; 94,061,740 and 80,466,735 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively 94 80 Additional paid-in capital 765,754 640,166 Accumulated other comprehensive income (loss) 3,673 (1,579 ) Accumulated deficit (464,785 ) (402,641 ) Total stockholders’ equity 304,736   236,026   Total liabilities and stockholders’ equity $ 501,817   $ 428,768    

Non-GAAP Financial Measures

In this press release, Spectrum reports certain historical “non-GAAP financial measures,” as defined in Regulation G of the Securities Exchange Act of 1934. Non-GAAP financial measures differ from financial statements reported in conformity to U.S. generally accepted accounting principles (“GAAP”). In accordance with Regulation G, we reconciled each non-GAAP financial measure to its most directly comparable GAAP measure. Management uses non-GAAP financial measures to assess our company’s performance and allocate company resources, and believes that providing these non-GAAP financial measures allows investors to view the Company’s financial results in the way that management views the financial results. We believe non-GAAP disclosures also provide investors with information used generally in our industry for evaluating operating results. Investors should not place undue reliance on non-GAAP financial measures, nor should investors consider non-GAAP financial measures as more meaningful than, or as substitutes or replacements for, financial measures prepared in accordance with GAAP.

The non-GAAP financial measures presented exclude the items summarized in the below table. Management believes that adjustments for these items assist investors in making comparisons of period-to-period operating results and that these items are not indicative of the Company’s on-going core operating performance.

The non-GAAP financial measures presented herein have certain limitations in that they do not reflect all of the costs associated with the operations of the Company’s business as reported under GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by the Company may be different from the non-GAAP financial measures used by other companies.

  SPECTRUM PHARMACEUTICALS, INC. Reconciliation of Non-GAAP Adjustments for Condensed Consolidated Statements of Operations

(In thousands, expect per share amounts)

        Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2017   2016 2017   2016 (1) GAAP product sales, net & license fees and service revenue $ 36,395 $ 33,393 $ 99,797 $ 111,208 Non GAAP adjustments to product sales, net & license fees and service revenue: (5,000 ) —   (5,000 ) (6,000 ) Non-GAAP product sales, net & license fees and service revenue $ 31,395   $ 33,393   $ 94,797   $ 105,208   (2) GAAP selling, general and administrative expenses $ 18,880 $ 19,465 $ 54,595 $ 69,047 Non GAAP adjustments to SG&A: Stock-based compensation (2,750 ) (2,650 ) (8,066 ) (8,209 ) Litigation expenses — (1,133 ) — (11,946 ) Depreciation expense (75 ) (103 ) (241 ) (432 ) Non-GAAP selling, general and administrative $ 16,055   $ 15,579   $ 46,288   $ 48,460   (3) GAAP research and development $ 13,878 $ 13,293 $ 43,670 $ 43,037 Non-GAAP adjustments to R&D: Stock-based compensation (660 ) (500 ) (1,588 ) (1,545 ) Depreciation expense (2 ) (3 ) (6 ) (9 ) Other R&D milestone payments —   —   —   (2,826 ) Non-GAAP research and development $ 13,216   $ 12,790   $ 42,076   $ 38,657   (4) GAAP net loss $ (18,709 ) $ (17,455 ) $ (62,144 ) $ (51,070 ) Non-GAAP adjustments to net loss: Adjustments to product sales, net & license fees and service revenue, SG&A, and R&D as noted above (1,513 ) 4,389 4,901 18,967 Adjustment to cost of sales 1,000 — 1,000 — Amortization and impairment charges of intangible assets 6,928 6,907 20,718 19,052 Adjustments to other expense, net 4,557 1,358 7,655 5,052 Adjustments to provision (benefit) for income taxes (1,466 ) (464 ) (1,412 ) (635 ) Non-GAAP net loss $ (9,203 ) $ (5,265 ) $ (29,282 ) $ (8,634 ) (5) GAAP loss per share (Basic and Diluted) $ (0.22 ) $ (0.22 ) $ (0.78 ) $ (0.73 ) Non-GAAP loss per share (Basic and Diluted) Basic and diluted $ (0.11 ) $ (0.07 ) $ (0.37 ) $ (0.12 ) Weighted average shares outstanding: Basic and diluted 83,463,153 79,303,380 80,177,370 70,437,885  

(1) Non-GAAP product sales, net & license fees and service revenue: These amounts reflect adjustments to reverse revenue recognition for upfront revenue from out-licenses and revenue from milestone achievement(s) that do not consistently recur. The resulting non-GAAP revenue solely consists of our (i) product sales, (ii) percentage-based royalties from our licensees’ sales, and (iii) on-going service revenue. We believe this measure of non-GAAP revenue is more indicative of the period-over-period success of our core ongoing product sales and service revenue.

(2) Non-GAAP selling, general and administrative: These amounts reflect adjustments to reverse allocated operating expenses for certain non-cash items (including stock-based compensation and depreciation), as well as the reversal of irregular operating expense items such as non-recurring legal fees and settlements. We believe the resulting non-GAAP SG&A value is more indicative of the period-over-period success of our administrative expense control, and more reflective of our normalized SG&A expense trends.

(3) Non-GAAP research and development: These amounts reflect adjustments to reverse allocated operating expenses for certain non-cash items (including stock-based compensation and depreciation), as well as non-recurring R&D milestone achievements that we record to expense for our in-licenses. We believe the resulting non-GAAP R&D value is more reflective of our true R&D expense trends.

(4) Non-GAAP net loss: These amounts reflect all non-GAAP adjustments described in (1) through (3) above, plus other non-cash and/or non-recurring items, including: (i) adjustments to reverse royalty expense on receipts from regulatory and sales milestone achievements; (ii) adjustments to reverse operating expenses for non-cash amortization and impairment of intangible assets (the reversal of these non-cash expenses allows for a clearer representation of the period-over-period success of our overall financial results and future working capital requirements); (iii) adjustments to reverse the impact of income taxes; and (iv) adjustments to reverse the impact of mark-to-market contingent consideration (although our contingent consideration results from prior acquisitions and is a part of our business strategy, these adjustments through earnings typically result from variables other than our current commercial activity or other operating performance measures that are a focus of our management), (v) reversal of foreign exchange gains and losses (noncash), and (vi) debt discount accretion expense (non-cash) for our convertible notes.

(5) Non-GAAP loss per share: These amounts reflect all non-GAAP adjustments in (1) through (4) above to present our overall non-GAAP financial results for each period on a per-share basis.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171102006465/en/

Spectrum Pharmaceuticals, Inc.Shiv KapoorVice President, Strategic Planning & Investor Relations702-835-6300InvestorRelations@sppirx.com